文献速递放疗物理与技术姑息放疗与转移瘤

质子再照射特殊医学物理会诊的初步经验

Initial Experience With Special Medical Physics Consultations for Proton Reirradiation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-08-19

该研究介绍了质子再照射特殊医学物理会诊(SMPC)的实施流程与初期临床影响,对192个再照射疗程进行基于形变配准的累积剂量分析,结果显示75%的会诊器官满足机构累积EQD2目标,25.5%的患者因SMPC而接受再优化。

要点

  • 质子再照射SMPC可标准化评估累积剂量并提示临床有意义的再优化。
  • 192个再照射疗程中,胸部、脑/全中枢、头颈和盆腔各占约20%。
  • SMPC后25.5%患者接受再优化,颈动脉是最常触发再优化的危及器官。

核心结论

  • 质子再照射SMPC的实施频繁触发临床有意义的再优化及针对配准不佳的缓解策略。
  • 该方法为危及器官累积剂量提供了标准化综合评估,有助于风险判断。

研究设计与样本

  • 单中心实施经验研究,基于文献由医生商定机构性危及器官EQD2目标,对物理剂量应用相对生物效应1.1后转换为EQD2。
  • SMPC对所有有DICOM-RT文件的患者进行基于形变配准的累积剂量分析,物理师评估配准质量并建议缓解策略。
  • 共分析192个质子再照射疗程,记录累积EQD2体积、既往剂量贡献、疗程间隔及SMPC触发的再优化和剂量学变化。

主要发现

  • 192个再照射疗程中26%为大分割或低分割,常见部位为胸部21%、脑/全中枢20%、头颈19%、盆腔19%。
  • 再照射中位间隔为33个月(四分位距16-63个月),胸部最短为16个月。
  • 会诊器官中满足机构累积EQD2目标的比例总体为75%。
  • 物理师将153/249(61.4%)的配准判定为可临床使用,并在剂量累积前处理了66/96(68.7%)的问题。
  • SMPC后25.5%的患者接受再优化,胸部32.6%、腹部/肝脏45.5%、脑/全中枢16.2%,颈动脉是最常触发再优化的危及器官。

关键数值与推荐

  • 机构性危及器官累积EQD2目标由医生基于 published literature 商定,物理剂量按相对生物效应1.1转换为EQD2。
  • 使用危及器官特异性α/β比值生成累积EQD2分布。
  • 配准可临床使用判定为153/249(61.4%),剂量累积前问题处理率为66/96(68.7%)。
  • 会诊器官满足机构累积EQD2目标的比例为75%。
  • SMPC后再优化比例为25.5%,其中胸部32.6%、腹部/肝脏45.5%、脑/全中枢16.2%。

临床怎么用

  • 对质子再照射患者应系统评估危及器官累积EQD2,而非仅看单程计划剂量。
  • 形变配准质量需由物理师审核,配准不佳时应先处理再累积剂量。
  • 颈动脉等关键危及器官的累积剂量评估可提示是否需要再优化。

局限性

  • 单中心实施经验,结果外推需谨慎。
  • 仅纳入有DICOM-RT文件的患者,可能存在选择偏倚。
  • 未报告再优化的具体剂量学变化数值及临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To reduce the volume of tissues receiving additional radiation dose, proton therapy is often used in patients receiving reirradiation (reRT). Standardized workflows to systematically assess cumulative dose and potential risks of reRT are limited. We present our institutional implementation of a proton reRT SMPC, characterizing its workflow and initial clinical impact. METHODS AND MATERIALS: Using published literature, physicians agreed upon institutional organs-at-risk (OARs) equivalent dose in 2-Gy fraction (EQD2) goals; constant relative biological effectiveness of 1.1 was applied to physical doses before EQD2 conversion. The SMPC used a deformable registration-based analysis of cumulative dose to OARs for all patients with available DICOM-RT files. Physicists assessed registration quality and suggested mitigation strategies. Using OAR-specific alpha/beta (α/β) ratios, cumulative EQD2 distributions were created. Cumulative EQD2 volumes, prior dose contributions, and time interval between courses were recorded for each OAR. SMPC-induced repeat plan optimizations ("reoptimization") and resulting dosimetric changes were recorded. RESULTS: Proton reRT SMPC with voxelwise EQD2 accumulation was performed for 192 reRT courses after center-wide implementation, 26% of which were hyper- or hypofractionated. Common disease sites were thorax (21%), brain/Craniospinal irradiation (20%), head and neck (19%), and pelvis (19%). Median reRT interval was 33 months (interquartile range, 16-63 months) from recent prior RT and the shortest for thorax (16 months). Overall percentage of consulted organs meeting institutional cumulative EQD2 goals was 75%. Physicists designated 153/249 (61.4%) registrations as acceptable for clinical use and addressed 66/96 (68.7%) of issues before dose accumulation. After SMPC, 25.5% of patients underwent reoptimization, most commonly for thoracic (32.6%) and abdominal/liver (45.5%) and least often for brain/Craniospinal irradiation (16.2%) reRT. Carotid artery was the most common OAR prompting reoptimization. CONCLUSIONS: Our experience demonstrates that implementation of a proton reRT SMPC frequently prompts clinically meaningful reoptimization and mitigation strategies for poor registration. Our methods provide a standardized comprehensive assessment of cumulative dose to OARs to inform risk assessment.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yoon SWP, Langen K, McDonald MW, et al. Initial Experience With Special Medical Physics Consultations for Proton Reirradiation. Int J Radiat Oncol Biol Phys. 2026. PMID: 42617885. doi:10.1016/j.ijrobp.2026.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。